The main objective of this study is to determine the incidence, type, and pattern of serious adverse events (SAEs), including but not limited to infections, liver and kidney events, and adverse events that lead to the discontinuation of Tecfidera in patients with Multiple Sclerosis.
This study will be conduted in patients with MS who have been newly prescribed Tecfidera under routine clincal care.
***OPEN TO ENROLLMENT***
To qualify, patients must:
- Have a diagnosis of Multiple Sclerosis
- Be naïve to Tecfidera
- Be 18 years of age or older
- Cannot be enrolled in any other clinical trial
Patients will be followed for up to 5 years and will be asked to complete approximately 5-6 online questionnaires after their routine clinic visits.
For more information, please contact Jeneane Henry, RN BSN, Clinical Research Nurse at 804-828-7802 or email@example.com.
Warren L. Felton III, MD (Principal Investigator), Dept. of Neurology at VCU
Unsong Oh, MD (Sub Investigator), Dept. of Neurology at VCU
Clinical Research Nurse / Study Coordinator:
Jeneane Henry, RN BSN, Dept. of Neurology at VCU